Regentis Biomaterials Advances GelrinC Toward U.S. Approval and European Commercialization

Regentis Biomaterials Ltd. (NYSE American: RGNT) is advancing GelrinC®, a cell-free hydrogel implant designed to simplify knee cartilage repair through a single-step, approximately 10-minute procedure that may offer an alternative to traditional microfracture and complex cell-based therapies. The company is targeting an estimated $3 billion U.S. market encompassing roughly 470,000 annual knee cartilage repair cases, where no approved off-the-shelf regenerative solution currently exists.

Clinical data have shown approximately 100% greater pain improvement versus microfracture, alongside MRI-confirmed regeneration of near-native cartilage and durable multi-year outcomes. GelrinC® has already secured CE Mark approval in Europe and is currently progressing through a pivotal U.S. Phase III trial that is more than 50% enrolled, positioning Regentis for several upcoming catalysts, including potential European commercialization, completion of the pivotal study, and eventual FDA submission.

The Gelrin platform technology is based on synchronized, degradable hydrogel implants that regenerate damaged or diseased tissue including inflamed cartilage and bone. GelrinC is eroded and resorbed in the knee, allowing surrounding cells to regenerate cartilage in a controlled process. This off-the-shelf solution aims to address a significant unmet need, as no such treatment is currently available in the U.S.

For more information, visit the company's corporate profile and newsroom.